Gene:
F7
coagulation factor VII (serum prothrombin conversion accelerator)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs510317 -348A>G, -348A>T, -402A>G, -402A>T, 113759754A>G, 113759754A>T, 1255760A>G, 1255760A>T, 4650A>G, 4650A>T
A > T
A > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs510335 -347G>A, -347G>C, -347G>T, -401G>A, -401G>C, -401G>T, 113759755G>A, 113759755G>C, 113759755G>T, 1255761G>A, 1255761G>C, 1255761G>T, 4651G>A, 4651G>C, 4651G>T
G > T
G > C
G > A
5' Flanking
No VIP available No Clinical Annotations available VA
rs6046 1047G>A, 1047G>C, 1047G>T, 113773159G>A, 113773159G>C, 113773159G>T, 1172G>A, 1172G>C, 1172G>T, 1238G>A, 1238G>C, 1238G>T, 1259G>A, 1259G>C, 1259G>T, 1269165G>A, 1269165G>C, 1269165G>T, 18055G>A, 18055G>C, 18055G>T, 986G>A, 986G>C, 986G>T, Arg329Gln, Arg329Leu, Arg329Pro, Arg391Gln, Arg391Leu, Arg391Pro, Arg413Gln, Arg413Leu, Arg413Pro
G > C
G > T
G > A
Not Available
Arg329Gln
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  FVII coagulation protein; eptacog alfa; factor VII
Alternate Symbols:  None
PharmGKB Accession Id: PA160

Details

Cytogenetic Location: chr13 : q34 - q34
GP mRNA Boundary: chr13 : 113760105 - 113774995
GP Gene Boundary: chr13 : 113750105 - 113777995
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
phenprocoumon
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
warfarin
No related diseases are available

Publications related to F7: 12

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers. European journal of clinical pharmacology. 2012. Mlynarsky Liat, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. European journal of clinical pharmacology. 2011. Geisen Christof, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy. Thrombosis and haemostasis. 2011. Luxembourg Baete, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. European journal of clinical pharmacology. 2009. Ohno Masako, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin. European journal of clinical pharmacology. 2009. Fuchshuber-Moraes Mateus, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics. 2009. Scott Stuart A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study. Pharmacogenetics and genomics. 2009. Maitland-van der Zee Anke-Hilse, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C9 and VKORC1 genetic polymorphism analysis might be necessary in patients with Factor V Leiden and prothrombin gene G2021A mutation(s). Diagnostic molecular pathology : the American journal of surgical pathology, part B. 2007. Leung Allen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin. Thrombosis and haemostasis. 2005. Rost Simone, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica. 2004. D'Ambrosio Rosa Lucia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood. 2004. Shikata Eriko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction of fibrinolysis and prothrombotic risk factors in neonates, infants and children with and without thromboembolism and underlying cardiac disease. a prospective study. Thrombosis research. 2001. Nowak-Göttl U, et al. PubMed

LinkOuts

Entrez Gene:
2155
OMIM:
227500
UCSC Genome Browser:
NM_000131
RefSeq RNA:
NM_000131
NM_019616
RefSeq Protein:
NP_000122
NP_062562
RefSeq DNA:
AC_000056
AC_000145
NC_000013
NG_009262
NT_027140
NW_001838085
NW_925517
UniProtKB:
FA7_HUMAN (P08709)
Ensembl:
ENSG00000057593
GenAtlas:
F7
GeneCard:
F7
MutDB:
F7
ALFRED:
LO007997G
HuGE:
F7
Comparative Toxicogenomics Database:
2155
ModBase:
P08709
HumanCyc Gene:
HS00709
HGNC:
3544

Common Searches